Detalhe da pesquisa
1.
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Cancer
; 125(18): 3208-3218, 2019 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31246283
2.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
N Engl J Med
; 375(19): 1856-1867, 2016 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27718784
3.
Integrated Fluidic Circuits for Single-Cell Omics and Multi-omics Applications.
Adv Exp Med Biol
; 1129: 19-26, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30968358
4.
Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.
Br J Haematol
; 182(4): 495-503, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29808907
5.
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Oncologist
; 23(9): 1079-1082, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29866947
6.
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.
Blood
; 127(23): 2833-40, 2016 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27091875
7.
Predicting Nucleation of Isonicotinamide from the Solvent-Solute Interactions of Isonicotinamide in Common Organic Solvents.
J Phys Chem A
; 122(12): 3301-3312, 2018 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29510046
8.
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Lancet Oncol
; 18(8): 1104-1115, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28651929
9.
Surface layer proteins from virulent Clostridium difficile ribotypes exhibit signatures of positive selection with consequences for innate immune response.
BMC Evol Biol
; 17(1): 90, 2017 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28335725
10.
The nature and nurture of cell heterogeneity: accounting for macrophage gene-environment interactions with single-cell RNA-Seq.
BMC Genomics
; 18(1): 53, 2017 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28061811
11.
Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
Br J Haematol
; 175(3): 448-456, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27434748
12.
Modified transurethral resection of the prostate (TURP) for men with moderate lower urinary tract symptoms (LUTS) before brachytherapy is safe and feasible.
BJU Int
; 115(4): 580-6, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24802744
13.
Clinical and diagnostic findings in patients with elevated cerebrospinal bilirubin.
Postgrad Med J
; 91(1082): 675-80, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26489767
14.
Analysis of SARS-CoV-2 antibody seroprevalence in Northern Ireland during 2020-2021.
Heliyon
; 10(2): e24184, 2024 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38304848
15.
A role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteins.
PLoS Pathog
; 7(6): e1002076, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21738466
16.
Synergy Assessment of Four Antimicrobial Bioactive Compounds for the Combinational Treatment of Bacterial Pathogens.
Biomedicines
; 11(8)2023 Aug 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37626713
17.
Colon cancer associated genes exhibit signatures of positive selection at functionally significant positions.
BMC Evol Biol
; 12: 114, 2012 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22788692
18.
Erratum to: Surface layer proteins from virulent Clostridium difficile ribotypes exhibit signatures of positive selection with consequences for innate immune response.
BMC Evol Biol
; 17(1): 135, 2017 06 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28606132
19.
Microfluidic live tracking and transcriptomics of cancer-immune cell doublets link intercellular proximity and gene regulation.
Commun Biol
; 5(1): 1231, 2022 11 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36371461
20.
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.
Int J Cancer
; 129(1): 245-55, 2011 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21170960